Qiming Venture Partners and Its Investors Named to Diyixinsheng's 2025 China Investment Institutions and Individuals Rankings
Designed to unearth a genuine "founder's guide to fundraising, an LP's investment reference."
Recently, Diyixinsheng released its 2025 China Investment Institutions and Individuals Rankings, evaluating firms across investment activity, fundraising, exits, IPOs, service transactions, post-investment tech support, and market influence — with the goal of producing "a true entrepreneur's guide to fundraising and a reference for LP investment decisions."
Qiming Venture Partners was named to the lists of China's Most Active Venture Capital Institutions, China's Top VC Exits, Most Active Healthcare Investors, and Most Active AI Investors. William Hu, Managing Partner at Qiming Venture Partners, was named to China's Best Investors list. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation, was named to China's Best Sector Investors list. Shuo Mao, Executive Director at Qiming Venture Partners, was named to China's Best Young Investors list.
Qiming Venture Partners named to
China's Most Active Venture Capital Institutions
China's Top VC Exits
Most Active Healthcare Investors
Most Active AI Investors
William Hu, Managing Partner at Qiming Venture Partners
named to
China's Best Investors
Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation
named to
China's Best Sector Investors
Shuo Mao, Executive Director at Qiming Venture Partners
named to
China's Best Young Investors
Selection Criteria
For this year's rankings, Diyixinsheng organized its 2025 survey (the 20th consecutive quarter) of nearly 100 institutions, focusing on domestic firms' investment and transaction volume, deal value, fundraising and IPO performance, market influence, and any major negative developments. Data was drawn primarily from self-reported institutional submissions and direct research, supplemented by public data from IT Juzi and Tianyancha.
Diyixinsheng noted that in 2025, China's equity investment market completed a critical shift from "scale expansion" to "value creation" amid deep structural adjustment. For the full year, investment activity demonstrated resilience through volatility, with a pronounced "year-end rally" in Q4 — both market activity and capital scale exceeded annual averages, delivering strong momentum to close out the year. Meanwhile, China's GDP grew 5.0% year-over-year, meeting the annual target, with the stable macroeconomic outlook providing a solid foundation for the structural optimization of the equity investment market. The investment logic around technological innovation underwent a profound shift in 2025, as venture capital's microscope moved from surface-level metrics down to underlying technology.
Source | Diyixinsheng
Past Coverage
Qiming Weekly | 10 Updates from Qiming Venture Partners Portfolio Companies Vol.09, 2026.3.17
Qiming Honors | Five Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on early and growth-stage investments in Technology and Healthcare Innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), HEC Pharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.